Athenex has been granted a patent for a pharmaceutical composition that enhances taxane absorption for cancer treatment. The composition includes specific surfactants in precise ratios, increasing absorption compared to traditional methods. The method involves orally administering the composition to individuals in need of cancer treatment. GlobalData’s report on Athenex gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Athenex, Cancer treatment biomarkers was a key innovation area identified from patents. Athenex's grant share as of May 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
Oral cancer treatment method using taxane surfactant mixture
A recently granted patent (Publication Number: US11963942B2) discloses a method for treating cancer by orally administering a pharmaceutical composition containing a taxane solution and a specific surfactant mixture. The composition is designed to form a micellar suspension and includes a first surfactant (polysorbate 80) and a second surfactant (propane-1,2,3-triol-oxirane) in a specific weight ratio. Additionally, the method involves administering a P-glycoprotein inhibitor to enhance the treatment's effectiveness. The taxane used can be selected from various options like paclitaxel, docetaxel, cabazitaxel, larotaxel, ortataxel, and tesetaxel. The inclusion of stabilizers like citric acid or ascorbic acid further enhances the pharmaceutical composition's stability and efficacy.
Moreover, the patent also covers a method to increase taxane oral bioavailability, peak plasma concentration, and area under the curve by using a similar pharmaceutical composition with the specified surfactant mixture. This method also involves administering a P-glycoprotein inhibitor to the individual. The taxane options remain the same, and the stabilizers can include citric acid or ascorbic acid. The patent emphasizes the importance of the specific surfactant mixture and its ratio in achieving the desired micellar suspension for effective cancer treatment. The inclusion of a P-glycoprotein inhibitor further enhances the treatment's outcomes, making this method a promising approach in cancer therapy.
To know more about GlobalData’s detailed insights on Athenex, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
